RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.